280 related articles for article (PubMed ID: 16844454)
1. Prevention and management of osteoporosis in men receiving androgen deprivation therapy: a survey of urologists and radiation oncologists.
Alibhai SM; Rahman S; Warde PR; Jewett MA; Jaffer T; Cheung AM
Urology; 2006 Jul; 68(1):126-31. PubMed ID: 16844454
[TBL] [Abstract][Full Text] [Related]
2. Bone health management in men undergoing ADT: examining enablers and barriers to care.
Damji AN; Bies K; Alibhai SM; Jones JM
Osteoporos Int; 2015 Mar; 26(3):951-9. PubMed ID: 25526712
[TBL] [Abstract][Full Text] [Related]
3. Osteoporosis due to androgen deprivation therapy in men with prostate cancer.
Daniell HW
Urology; 2001 Aug; 58(2 Suppl 1):101-7. PubMed ID: 11502461
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines.
Cheung AS; Pattison D; Bretherton I; Hoermann R; Lim Joon D; Ho E; Jenkins T; Hamilton EJ; Bate K; Chan I; Zajac JD; Grossmann M
Andrology; 2013 Jul; 1(4):583-9. PubMed ID: 23686896
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
6. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.
Alibhai SM; Mohamedali HZ; Gulamhusein H; Panju AH; Breunis H; Timilshina N; Fleshner N; Krahn MD; Naglie G; Tannock IF; Tomlinson G; Warde P; Duff Canning S; Cheung AM
Osteoporos Int; 2013 Oct; 24(10):2571-9. PubMed ID: 23563932
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of bone mass density on patients with prostate cancer prior to the start of androgen deprivation therapy.
Ziaran S; Goncalves FM; Wendl J; Trebaticky B; Breza JS
Bratisl Lek Listy; 2009; 110(9):559-62. PubMed ID: 19827339
[TBL] [Abstract][Full Text] [Related]
8. Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial.
Alibhai SMH; Breunis H; Timilshina N; Hamidi MS; Cheung AM; Tomlinson GA; Manokumar T; Samadi O; Sandoval J; Durbano S; Warde P; Jones JM
Cancer; 2018 Mar; 124(6):1132-1140. PubMed ID: 29211305
[TBL] [Abstract][Full Text] [Related]
9. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
[TBL] [Abstract][Full Text] [Related]
10. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
[TBL] [Abstract][Full Text] [Related]
11. GU radiation oncologists consensus on bone loss from androgen deprivation.
Duncan GG; Corbett T; Lukka H; Warde P; Pickles T
Can J Urol; 2006 Feb; 13(1):2962-6. PubMed ID: 16515750
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
13. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
[TBL] [Abstract][Full Text] [Related]
14. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
Dhanapal V; Reeves DJ
J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
[TBL] [Abstract][Full Text] [Related]
15. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
16. Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer.
Panju AH; Breunis H; Cheung AM; Leach M; Fleshner N; Warde P; Duff-Canning S; Krahn M; Naglie G; Tannock I; Tomlinson G; Alibhai SM
BJU Int; 2009 Mar; 103(6):753-7. PubMed ID: 19007370
[TBL] [Abstract][Full Text] [Related]
17. Management of osteoporosis in men on androgen deprivation therapy.
Adler RA
Maturitas; 2011 Feb; 68(2):143-7. PubMed ID: 21129866
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
[TBL] [Abstract][Full Text] [Related]
19. Osteoporosis during androgen deprivation therapy for prostate cancer.
Smith MR
Urology; 2002 Sep; 60(3 Suppl 1):79-85; discussion 86. PubMed ID: 12231056
[TBL] [Abstract][Full Text] [Related]
20. Bone health care for patients with prostate cancer receiving androgen deprivation therapy.
Tsang DS; Alibhai SM
Hosp Pract (1995); 2014 Apr; 42(2):89-102. PubMed ID: 24769788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]